HiberCell is a series b startup based in United States. 1 investor tracked.
HiberCell is a company headquartered in the United States. Brouky records 3 investors associated with the company.
HiberCell is a biotechnology company developing therapeutics that target the integrated stress response (ISR) to treat cancer. It is advancing therapy candidates in clinical trials for indications related to treatment resistance, relapse, and metastasis.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.